Faculty introduction, disclosures

Introduction content Statistics and risk stratification MM treatment paradigm

Updates in treatment and monitoring of patients with RRMM Treatment history and therapeutic objectives ·      Present pharmacotherapy, clinical trial findings, and guideline updates o   Treatment of first relapses §  Lenalidomide sensitive §  Treatment options when refractory to: ·       Lenalidomide alone ·       Lenalidomide and bortezomib ·       Lenalidomide and daratumumab o   Treatment of later relapses §  Regimens including agents to which the patient’s disease is not already refractory: pomalidomide, carfilzomib, isatuximab, elotuzumab, ixazomib, selinexor §  Penta-refractory disease ·       Therapy aimed at B cell maturation antigen (BCMA) via chimeric antigen receptor T cell (e.g., idecabtagene vicleucel or ciltacabtagene autoleucel) or antibody conjugate (e.g., belantamab mafodotin) therapy ·       Nuclear export inhibition ·       Alkylator-containing regimens ·       Investigational therapies targeting: Bcl-2; Bruton tyrosine kinase; BCMA ·       Disease response and relapse monitoring o   Timing o   Assessment: serum protein electrophoresis, 24-hour urine protein electrophoresis, free light chain assay, and minimum residual disease ·       Additional considerations and challenges o   Treatment-emergent adverse effects and their management o   Other patient-related factors: age-related frailty, acute renal failure, extramedullary disease o   Pandemic-related considerations o   Patient education, shared decision-making, and patient-reported outcomes o   Disparities in care Patient cases

Summary, conclusions, and best practice recap

By the end of the session the participant will be able to:

• Describe guideline-recommended therapy for RRMM.
• Recall first- and later-line pharmacotherapies for RRMM.
• Describe emerging treatment options presently available for RRMM, their mechanisms of action and safety, and anticipated place in therapy.
• Summarize the healthcare burden unique to patients with RRMM and related challenges to effective disease management.
• Develop a treatment plan for a patient with RRMM.

ACCME Activity #202340979

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Faculty Disclosure: Scott Goldsmith, MD, Assistant Professor, Division of Myeloma, City of Hope National Medical Center, has received financial compensation from Janssen, Sanofi-Genzyme, Wugen, Adaptive Biosciences, and Oncovalent for consulting and/or advisory board work.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty will discuss off-label uses.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Takeda.

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

*Required to view Printable PDF Version